Global Blood Therapeutics, Inc.
GBT · NASDAQ
6/30/2022 | 3/31/2022 | 12/31/2021 | 9/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.61 | -0.20 | -6.32 |
| FCF Yield | -2.13% | -3.21% | -3.65% | -4.09% |
| EV / EBITDA | -34.83 | -35.51 | -23.00 | -22.28 |
| Quality | ||||
| ROIC | -9.45% | -9.19% | -10.20% | -12.49% |
| Gross Margin | 98.03% | 98.09% | 97.94% | 98.41% |
| Cash Conversion Ratio | 0.54 | 0.88 | 0.78 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | 70.09% | 135.11% | 352.07% | 5,645,541.04% |
| Free Cash Flow Growth | 38.02% | -4.53% | -5.20% | -45.35% |
| Safety | ||||
| Net Debt / EBITDA | -5.55 | -3.78 | 0.31 | 2.35 |
| Interest Coverage | -8.79 | -8.90 | -18.94 | -18.14 |
| Efficiency | ||||
| Inventory Turnover | 0.02 | 0.02 | 0.02 | 0.02 |
| Cash Conversion Cycle | 3,703.43 | 4,868.73 | 3,407.95 | 4,689.87 |